Abiomed Announces Q2 FY 2018 Revenue of $132.8 Million, Up 29% and Record U.S. Patient Utilization, Up 33%
DANVERS, Mass., Oct. 26, 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, today reported second quarter fiscal 2018 revenue of $132.8 million, an increase of 29% compared to revenue of $103.0 million for the same period of fiscal 2017. Second quarter fiscal 2018 GAAP net income was $24.5 million or $0.54 per diluted share, compared to GAAP net income of $8.9 million or $0.20 per diluted share for the prior year period.
Financial and operating highlights during the second quarter of fiscal 2018 include:
Worldwide revenue from Impella heart pumps totaled $127.4 million, an increase of 30% compared to revenue of $97.9 million during the same period of the prior year. U.S. revenue from Impella pumps grew 27% to $113.6 million and U.S. patient usage grew 33%.
Outside the U.S., revenue from Impella heart pumps totaled $13.8 million and was up 61%, predominantly from Germany, which grew 64% in revenue from the prior year with record number of patients.
The installed base for Impella 2.5® heart pumps in the U.S. grew by an additional 17 hospitals, which made initial purchases of Impella heart pumps, bringing the installed customer base to 1,171 sites. The installed customer base for Impella CP® heart pumps grew by 31 new U.S. hospitals, bringing the total number of Impella CP sites to 1,093. The installed customer base for Impella 5.0® heart pumps grew by 12 new U.S. hospitals, bringing the total number of Impella 5.0 sites to 484.
An additional 44 sites made initial purchases of Impella RP® heart pumps during the quarter, bringing the total number of sites to 186.
Gross margin of 84% compared to 83% of the prior year.
Operating income was $31.7 million, or 24% operating margin, compared to $14.5 million, or 14% operating margin in the prior year.
GAAP net income was $24.5 million or $0.54 per diluted share, which benefited from a new accounting standard that required $4.5 million, or $0.10 per diluted share, of excess tax benefits related to employee share-based compensation awards be recorded as a reduction of income tax expense. This compared to GAAP net income of $8.9 million or $0.20 per diluted share for the prior year, before the new accounting standard.
The Company generated $30.1 million in cash, cash equivalents and marketable securities, totaling $319.2 million as of September 30, 2017, compared to $289.1 million at June 30, 2017. The Company currently has no debt.
On September 20, 2017, Abiomed received FDA PMA approval for the Impella RP heart pump. With this approval, the Impella RP heart pump is the only percutaneous temporary ventricular support device that is FDA-approved as safe and effective for right heart failure.
Today, Abiomed announced in a separate press release the first patient treated with Impella® heart pump in Japan. The Impella 2.5 and Impella 5.0 heart pumps are approved for the treatment of drug-resistant acute heart failure and are the first and only percutaneous temporary ventricular support devices approved by the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan.
"This quarter, we set new records for supporting patients in the U.S. and Germany and we continue to observe improved clinical outcomes with our education and training initiatives," said Michael R. Minogue, Chairman, President and Chief Executive Officer, Abiomed. "I am proud of the team's ability to consistently adapt and execute as we transform the standard of care and build the Field of Heart Recovery."
FISCAL YEAR 2018 OUTLOOK
The Company is again increasing the lower end of its fiscal year 2018 revenue guidance by $5 million to a new range of $565 million to $575 million, an increase in revenue of 27% to 29% from the prior year. This compares to the Company's initial forecast of $555 million to $575 million and a 25% to 29% increase from the prior year. The Company is also increasing its fiscal year guidance for GAAP operating margin to the range of 23% to 25%, from 22% to 24%.
The Company will host a conference call to discuss the results on Thursday, October 26, 2017, at 8:00 a.m. EDT. Michael R. Minogue, Chairman, President and Chief Executive Officer and Robert L. Bowen, former Chief Financial Officer, will host the conference call.
To listen to the call live, please tune into the webcast via http://investor.abiomed.com or dial (855) 212-2361; the international number is (678) 809-1538. A replay of this conference call will be available beginning at 11 a.m. EDT October 26, 2017 through 11:00 a.m. EDT on October 29, 2017. The replay phone number is (855) 859-2056; the international number is (404) 537-3406. The replay access code is 95924236.
The ABIOMED logo, ABIOMED, Impella, Impella CP, and Impella RP are registered trademarks of Abiomed, Inc. in the U.S. and in certain foreign countries. Impella 2.5, Impella 5.0, and Recovering hearts. Saving lives. are trademarks of Abiomed, Inc.
Based in Danvers, Massachusetts, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support. Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. For additional information, please visit: www.abiomed.com
This release contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, and future opportunities and expected regulatory approvals. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, including the potential for future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, litigation matters, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.
|Abiomed, Inc. and Subsidiaries|
|Consolidated Balance Sheets|
|(in thousands, except share data)|
|September 30, 2017||March 31, 2017|
|Cash and cash equivalents||$||44,536||$||39,040|
|Short-term marketable securities||218,661||190,908|
|Accounts receivable, net||57,327||54,055|
|Prepaid expenses and other current assets||9,014||8,024|
|Total current assets||370,170||326,958|
|Long-term marketable securities||55,954||47,143|
|Property and equipment, net||97,697||87,777|
|In-process research and development||16,016||14,482|
|Long-term deferred tax assets, net||106,798||34,723|
|LIABILITIES AND STOCKHOLDERS' EQUITY|
|Current portion of capital lease obligation||851||799|
|Total current liabilities||63,358||69,617|
|Other long-term liabilities||598||3,251|
|Long-term deferred tax liabilities||866||783|
|Capital lease obligation, net of current portion||15,110||15,539|
|Commitments and contingencies|
|Class B Preferred Stock, $.01 par value||-||-|
|Authorized - 1,000,000 shares; Issued and outstanding - none|
|Common stock, $.01 par value||442||437|
| Authorized - 100,000,000 shares; Issued - 45,921,029 shares at September 30, 2017 and 45,249,281
shares at March 31, 2017
| Outstanding - 44,200,784 shares at September 30, 2017 and 43,673,286 shares
at March 31, 2017
|Additional paid in capital||592,081||565,962|
|Retained earnings (accumulated deficit)||90,164||(46,959||)|
|Treasury stock at cost - 1,720,245 shares at September 30, 2017 and 1,575,995 shares at March 31, 2017||(65,999||)||(46,763||)|
|Accumulated other comprehensive loss||(11,802||)||(20,606||)|
|Total stockholders' equity||604,886||452,071|
|Total liabilities and stockholders' equity||$||694,653||$||550,414|
|Abiomed, Inc. and Subsidiaries|
|Consolidated Statements of Operations|
|(in thousands, except per share data)|
Three Months Ended
Six Months Ended
|Funded research and development||41||27||78||33|
|Costs and expenses:|
|Cost of product revenue||21,627||17,309||43,489||32,379|
|Research and development||19,390||18,052||36,321||33,712|
|Selling, general and administrative||60,080||53,086||120,677||104,118|
|Income from operations||31,726||14,508||64,804||35,741|
|Investment income, net||781||342||1,416||611|
|Other (expense) income, net||(23||)||(114||)||56||(191||)|
|Income before income taxes||32,484||14,736||66,276||36,161|
|Income tax provision (1)||7,981||5,861||4,399||14,376|
|Basic net income per share||$||0.56||$||0.21||$||1.41||$||0.51|
|Basic weighted average shares outstanding||44,141||43,129||44,018||42,971|
|Diluted net income per share (2)||$||0.54||$||0.20||$||1.36||$||0.49|
|Diluted weighted average shares outstanding||45,698||44,580||45,655||44,493|
|(1) Income tax provision includes the effect of the following item:|
|Excess tax benefits related to stock-based compensation awards *||$||4,434||$||-||$||21,276||$||-|
|(2) Diluted net income per share includes the effect of the following item:|
|Excess tax benefits related to stock-based compensation awards *||$||0.10||$||-||$||0.47||$||-|
| * In the first quarter of fiscal 2018, the Company adopted Accounting Standards Update No. 2016-09, Improvements to Employee Share-Based Payment
Accounting, which requires that all excess tax benefits and tax deficiencies related share-based compensation arrangements be recognized as income tax benefit
or expense, instead of in stockholders' equity as previous guidance required.
For further information please contact:
Director, Investor Relations
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Abiomed via Globenewswire
Följ NASDAQ OMX
Abonnera på våra pressmeddelanden.
Senaste pressmeddelandena från NASDAQ OMX
P&WC's FAST(TM) Solution to Bring Data-Driven Predictability to Operators of the PT6A-67P-powered Pilatus PC-12 NG Aircraft28.5.2018 08:00 | Pressmeddelande
Launching on PlaneSense's fleet of PC-12 aircraft, the FAST(TM) solution will help drive reduced costs and increased availability for the leading fractional operator GENEVA, Switzerland, May 28, 2018 (GLOBE NEWSWIRE) -- Pratt & Whitney Canada (P&WC) has achieved Supplemental Type Certification (STC) for its FAST(TM) prognostics solution on the single-engine Pilatus PC-12 47E NG aircraft powered by the PT6A-67P. The FAST solution captures and analyzes full-flight engine and aircraft data, enabling high visibility on a multitude of key operating parameters within 15 minutes of the pilot shutting down the engine, which can be used to optimize maintenance planning and operations and further increase aircraft availability. P&WC is a subsidiary of United Technologies Corporation (NYSE:UTX). PlaneSense, a leading fractional aircraft ownership program, will launch the FAST solution on its fleet of PC-12 NG aircraft. "We at PlaneSense have always been focused on safety, reliability, and maintai
Medibio Corporate Health Extends Global Footprint Signing Contract with Jacobs Engineering25.5.2018 16:38 | Pressmeddelande
Jacobs, one of the world's largest engineering and environmental consultancy groups, has more than 70,000 employees globally SYDNEY, Australia and MINNEAPOLIS, May 25, 2018 (GLOBE NEWSWIRE) -- Medibio Limited (MEB or the Company) (ASX:MEB) (OTCQB:MDBIF), a mental health technology company, today announced a significant contract for Medibio's Corporate Health product with Dallas, TX-based Jacobs Engineering across their Asia Pacific, Middle East, and European divisions. Through the Mental Health Check-In, companies can offer employees an end-to-end mental health program, direct to their devices, to see how the mind and body are tracking. It's a personalized, private, and objective way to see the unseeable: mental health issues in the workplace. Employees are provided the opportunity to confidentially check-in on their mental health and receive personalized confidential results from both an objective biometric screening in conjunction with a 12-minute subjective survey. Employers receive
LeoVegas warms up ahead of FIFA World Cup with launch of sportsbook 2.0 and new design25.5.2018 14:20 | Pressmeddelande
LeoVegas is conducting constant development to further improve the gaming experience with the launch of sportsbook 2.0 and a new design for Leovegas.com. It strengthens LeoVegas mobile position and increases the competitiveness within sports betting. "Our new design has been created to give our customers a better overview of all games in all product verticals," comments Gustaf Hagman, CEO of LeoVegas. "The design features a simplified and more intuitive experience, which is especially important in sport, where relevance and simplicity are key factors. On top of this we are launching a number of updates and expanding ownership of the sportsbook. Together this builds further on creating a world class gaming experience and is in line with our passion "Leading the way into the mobile future". This will give us the right conditions ahead of the World Cup, but it also represents a long-term springboard towards building the world's best mobile sportsbook". Improved sports betting experience L
LeoVegas värmer upp inför fotbolls VM och lanserar sportbok 2.0 med ny design25.5.2018 14:19 | Pressmeddelande
Det sker en ständig utveckling av LeoVegas och för att förbättra spelupplevelsen ytterligare lanseras nu sportbok 2.0 samt en ny design av LeoVegas.com. Det stärker LeoVegas mobila position och ökar konkurrenskraften inom sportsbetting. "Vår nya design är skapad för att ge våra kunder en bättre överblick för alla spel inom samtliga produktvertikaler. Designen ger en förenklad och mer intuitiv upplevelse vilket är särskilt viktigt inom sport där relevans och enkelhet är nyckelfaktorer. Utöver det lanserar vi ett flertal uppdateringar samt ökar ägarskapet av sportboken. Tillsammans bygger det vidare på att skapa en spelupplevelse i världsklass och går i linje med vår passion "Leading the way to the mobile future". Detta ger oss rätt förutsättningar inför VM men de är också ett långsiktigt avstamp till att bygga världens bästa mobila sportbok. säger Gustaf Hagman, CEO LeoVegas. Förbättrad sportupplevelse LeoVegas har nu ägarskap över flera sidor som leverantören Kambi tidigare hade kontro
VIRGIN PULSE ANNOUNCES INDUSTRY-LEADING GDPR COMPLIANCE25.5.2018 14:00 | Pressmeddelande
Virgin Pulse Extends the GDPR's Strong Data Privacy Rights to All Clients and Members Across the Globe PROVIDENCE, R.I., May 25, 2018 (GLOBE NEWSWIRE) -- Virgin Pulse, the leading global provider of digital employee health, wellbeing and engagement solutions, today announced that it has achieved compliance with the EU General Data Protection Regulation (GDPR) for the Virgin Pulse platform. The company has also appointed Associate Counsel Beatrice Botti as Data Protection Officer (DPO) to oversee the Virgin Pulse privacy program. With this achievement, Virgin Pulse leads the market as the first company in the wellbeing and engagement industry to fully meet the comprehensive standards of the new GDPR data privacy law. The company has completed a thorough review of its internal data collection, storage and handling processes and implemented enhancements to achieve GDPR compliance and give all Virgin Pulse customers and members greater control over their personal data. The GDPR is the firs
Resverlogix Provides Unrestricted Educational Grant for Epigenetic Symposium at International Renal Congress25.5.2018 07:45 | Pressmeddelande
CALGARY, Alberta, May 24, 2018 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) today announced that on Friday, May 25, 2018, at the European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) Congress in Copenhagen, Denmark, the Company is supporting a symposium titled: "Epigenetics in CKD & CVD: A potential breakthrough therapy?" The symposium highlights the role of epigenetics and BET-inhibition in chronic kidney disease and cardiovascular disease, especially in patients with diabetes mellitus, and the significant unmet need that still exists in this patient population. The symposium is co-chaired by Vincent M. Brandenburg, MD - Nephrologist, Aachen, Germany and Kamyar Kalantar-Zadeh, MD - UC Irvine School of Medicine, Irvine, CA, USA, both leading scientists also serving as advisors to Resverlogix's Renal program. The speakers and agenda are as follows: Introduction Vincent M. Brandenburg, MD - University Hospital of the RWTH
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum